Literature DB >> 31520087

[Implant clarification : Management in clinical practice].

P Bauer1.   

Abstract

BACKGROUND: The increasing number of magnetic resonance imaging (MRI) examinations and the increasing number of medical implants lead to an ever-increasing expenditure in implant research, which as a consequence is becoming more time and resource consuming.
MATERIAL AND METHODS: This review article provides guidelines for optimized implant clarification in clinical practice by means of patient interrogation and the incorporation of implant databases. The technical background of implant interactions is discussed and an outlook on new integrated MRI safety systems is given.
CONCLUSION: The optimization of the implant clarification process integrated into the clinical workflow avoids undesired MRI interactions and enables a safe and economic working procedure for patients.

Entities:  

Keywords:  Interactions; Magnetic resonance imaging; Research; Spatial field gradient; Specific absorption rate

Mesh:

Year:  2019        PMID: 31520087     DOI: 10.1007/s00117-019-00591-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  3 in total

1.  ACR guidance document on MR safe practices: 2013.

Authors:  Emanuel Kanal; A James Barkovich; Charlotte Bell; James P Borgstede; William G Bradley; Jerry W Froelich; J Rod Gimbel; John W Gosbee; Ellisa Kuhni-Kaminski; Paul A Larson; James W Lester; John Nyenhuis; Daniel Joe Schaefer; Elizabeth A Sebek; Jeffrey Weinreb; Bruce L Wilkoff; Terry O Woods; Leonard Lucey; Dina Hernandez
Journal:  J Magn Reson Imaging       Date:  2013-01-23       Impact factor: 4.813

2.  [MR implant labelling and its use in clinical MRI practice].

Authors:  M Mühlenweg; G Schaefers
Journal:  Radiologe       Date:  2015-08       Impact factor: 0.635

3.  Recommended responsibilities for management of MR safety.

Authors:  Fernando Calamante; Bernd Ittermann; Emanuel Kanal; David Norris
Journal:  J Magn Reson Imaging       Date:  2016-06-03       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.